The leaders of the G20 convened in Rome Friday for the Global Health Summit, where they made specific commitments to global vaccine access that are very much aligned with BIO’s views and proposed SHARE Program.
The G20 leaders signed the Rome Declaration, which “reaffirms continued multilateral support for preparedness, prevention, detection, and response to the pandemic, as well as appropriate and sustainable funding for collaborative global response efforts, especially the Access to COVID-19 Tools (ACT) Accelerator,” explains Global Citizen.
The declaration emphasizes the importance of “global sharing of safe, effective, quality, and affordable vaccine doses,” as well as the need for sufficient funding for the ACT Accelerator and COVAX.
They also affirmed support for “efforts to strengthen supply chains and boost and diversify global vaccine-manufacturing capacity,” noting the importance of the COVAX Manufacturing Task Force. (BIO is a partner.)
Read the declaration.
In addition, biopharmaceutical manufacturers pledged 1.3 billion vaccine doses at low cost/no profit to low- and middle-income countries by the end of 2021. These include 1 billion of Pfizer-BioNTech, 200 million of Johnson & Johnson, and 100 million of Moderna, with an additional 1 billion total pledged for 2022.
The G20 commitments are aligned with BIO’s views on the best ways to promote vaccine access worldwide. BIO’s proposed COVID Global Strategy for Harnessing Access Reaching Everyone (SHARE) Program calls on countries to work together to ensure sufficient global supply, share surplus doses (and specifically reduce trade barriers to sharing), and strengthen and support health care systems in low- and middle-income countries.
Dr. Michelle’s Diagnosis: BIO welcomes this important declaration of 20 world leaders on how to best combat the global COVID crisis, including its emphasis on expanding voluntary global partnerships, which BIO members are exploring every day. – BIO President & CEO Dr. Michelle McMurry-Heath
Listen: Why We Can and Must SHARE Vaccines with the Globe
More Health Care News:
The New York Times: Scientists partially restored a blind man’s sight with new gene therapy
“Using a technique called optogenetics, researchers added light-sensitive proteins to the man’s retina, giving him a blurry view of objects.”